Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0153863
DC FieldValue
dc.titleCytochrome P4501A2 metabolizes 17?-estradiol to suppress hepatocellular carcinoma
dc.contributor.authorRen J.
dc.contributor.authorChen G.G.
dc.contributor.authorLiu Y.
dc.contributor.authorSu X.
dc.contributor.authorHu B.
dc.contributor.authorLeung B.C.S.
dc.contributor.authorWang Y.
dc.contributor.authorHo R.L.K.
dc.contributor.authorYang S.
dc.contributor.authorLu G.
dc.contributor.authorLee C.G.
dc.contributor.authorLai P.B.S.
dc.date.accessioned2019-11-06T07:57:49Z
dc.date.available2019-11-06T07:57:49Z
dc.date.issued2016
dc.identifier.citationRen J., Chen G.G., Liu Y., Su X., Hu B., Leung B.C.S., Wang Y., Ho R.L.K., Yang S., Lu G., Lee C.G., Lai P.B.S. (2016). Cytochrome P4501A2 metabolizes 17?-estradiol to suppress hepatocellular carcinoma. PLoS ONE 11 (4) : e0153863. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0153863
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/161572
dc.description.abstractHepatocellular carcinoma (HCC) occurs more frequently in men than in women. It is commonly agreed that estrogen plays important roles in suppressing HCC development, however, the underlying mechanism remains largely unknown. Since estrogen is mainly metabolized in liver and its metabolites affect cell proliferation, we sought to investigate if the liver-specific cytochrome P450 1A2 (CYP1A2) mediated the inhibitory effect of estrogen on HCC. In this study, the expression of estrogen-metabolizing enzyme CYP1A2 was determined in HCC tissues and cell lines. Cell proliferation and apoptosis were assessed in cells with or without CYP1A2 overexpression. The levels of 17?-estradiol (E2) and its metabolite 2-methoxyestradiol (2-ME) were determined. A xenograft tumor model in mice was established to confirm the findings. It was found that CYP1A2 expression was greatly repressed in HCC. E2 suppressed HCC cell proliferation and xenograft tumor development by inducing apoptosis. The inhibitory effect was significantly enhanced in cells with CYP1A2 overexpression, which effectively conversed E2 to the cytotoxic 2-ME. E2 in combination with sorafenib showed an additive effect on HCC. The anti-HCC effect of E2 was not associated with estrogen receptors ER? and ER? as well as tumor suppressor P53 but enhanced by the approved anti-HCC drug sorafenib. In addition, HDAC inhibitors greatly induced CYP1A2 promoter activities in cancer cells, especially liver cancer cells, but not in non-tumorigenic cells. Collectively, CYP1A2 metabolizes E2 to generate the potent anti-tumor agent 2-ME in HCC. The reduction of CYP1A2 significantly disrupts this metabolic pathway, contributing the progression and growth of HCC and the gender disparity of this malignancy. © 2016 Ren et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subject2 methoxyestradiol
dc.subjectcatechol methyltransferase
dc.subjectcytochrome P450 1A2
dc.subjectcytochrome P450 3A4
dc.subjectestradiol
dc.subjectprotein p53
dc.subjectsorafenib
dc.subject2-methoxyestradiol
dc.subjectcarbanilamide derivative
dc.subjectCYP1A2 protein, human
dc.subjectcytochrome P450 1A2
dc.subjectestradiol
dc.subjectestrogen
dc.subjectestrogen receptor
dc.subjectestrogen receptor alpha
dc.subjectestrogen receptor beta
dc.subjectnicotinamide
dc.subjectprotein p53
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectapoptosis
dc.subjectArticle
dc.subjectcancer growth
dc.subjectcancer incidence
dc.subjectcancer inhibition
dc.subjectcell proliferation
dc.subjectclinical article
dc.subjectconcentration (parameters)
dc.subjectcontrolled study
dc.subjectcorrelational study
dc.subjectcytotoxicity
dc.subjectfemale
dc.subjecthormone metabolism
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman tissue
dc.subjectliver carcinogenesis
dc.subjectliver cell carcinoma
dc.subjectmale
dc.subjectmouse
dc.subjectnonhuman
dc.subjectprotein expression
dc.subjectprotein function
dc.subjectprotein protein interaction
dc.subjectsex difference
dc.subjectupregulation
dc.subjectanalogs and derivatives
dc.subjectanimal
dc.subjectBagg albino mouse
dc.subjectCarcinoma, Hepatocellular
dc.subjectdrug effects
dc.subjectliver
dc.subjectLiver Neoplasms
dc.subjectmetabolism
dc.subjectnude mouse
dc.subjecttumor cell line
dc.subjectAnimals
dc.subjectApoptosis
dc.subjectCarcinoma, Hepatocellular
dc.subjectCell Line, Tumor
dc.subjectCell Proliferation
dc.subjectCytochrome P-450 CYP1A2
dc.subjectEstradiol
dc.subjectEstrogen Receptor alpha
dc.subjectEstrogen Receptor beta
dc.subjectEstrogens
dc.subjectHumans
dc.subjectLiver
dc.subjectLiver Neoplasms
dc.subjectMale
dc.subjectMice
dc.subjectMice, Inbred BALB C
dc.subjectMice, Nude
dc.subjectNiacinamide
dc.subjectPhenylurea Compounds
dc.subjectReceptors, Estrogen
dc.subjectTumor Suppressor Protein p53
dc.typeArticle
dc.contributor.departmentBIOCHEMISTRY
dc.description.doi10.1371/journal.pone.0153863
dc.description.sourcetitlePLoS ONE
dc.description.volume11
dc.description.issue4
dc.description.pagee0153863
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0153863.pdf3.99 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons